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Allogeneic hematopoietic cell transplantation (allo-HCT)
with an HLA-identical sibling donor is the best postremis-
sion treatment for patients with non-good-risk acute myeloid
leukemia (AML) in first complete remission (CR) (1). For
patients who lack an HLA-identical sibling donor, transplan-
tation with an 8/8 or a 7/8 HLA-matched unrelated donor,
an HLA-haploidentical donor, or an unrelated umbilical cord
blood (UCB) are considered as valid alternatives (1).
Potential advantages of UCBT in comparison with bone
marrow (BMT) or peripheral blood stem cell (PBSCT) trans-
plantation include more rapid availability and, because UCB
is relatively deficient in mature T cells, a low incidence of
chronic GVHD despite a greater degree of accepted HLA
mismatching (2). Disadvantages of UCB include slower
engraftment and increased risks of graft failure, both due at
least in part to the low number of cells contained in one
UCB unit (2). A large study by the Center for International
Blood and Marrow Transplant Research and the Acute Leu-
kemia Working Party of the European Group for Blood and
Marrow transplantation assessed the impact of graft source
(unrelated PBSC, unrelated BMT or UCB) on transplantation
outcomes in a cohort of 1525 patients with acute leukemia
transplanted between 2002 and 2006 (3). Main observations
were that engraftment kinetics were slower in UCB recipient
than in BMT or PBSCT recipients. Incidences of grade II–
IV acute GVHD were lower after UCBT than after PBSCT
but similar in UCB and BMT recipients, while incidences of
chronic GVHD were lower in UCB recipients than in
patients transplanted with other stem cell sources. Finally,
although non-relapse mortality (NRM) was higher in UCB
patients than in those receiving HLA-matched BM or PBSC,
leukemia-free survival (LFS) was similar with each stem cell
source.
A possible bias of registry studies comparing UCBT with
BMT or PBSCT is that only patients who undergo allo-HCT
are taken into consideration. This might create an artificial
disadvantage for UCBT (which is rapidly available), while
patients scheduled for an unrelated allo-HCT can relapse
while waiting for an unrelated donor to be found. In the cur-
rent issue of the journal, Yanada et al. report the results of a
study that used a decision analysis technique with the aim of
comparing unrelated BMT with UCBT in patients with non-
good-risk AML in first CR. Decision analysis is an increas-
ingly used statistical technique that allows estimation of out-
come given multiple variations of initial conditions and
assumptions. The best treatment option is then determined
based on the area under the survival curves, thus taking into
consideration the impact of each early and late evens (4).
The study population included a cohort of 907 patients from
the Japan Adult Leukemia Study Group with intermediate-
or high-/very high-risk AML in CR1 given chemotherapy
only, and a cohort of 752 patients from Japan Society for
Hematopoietic Cell Transplantation transplanted with bone
marrows from an 8/8 (n = 331) or a 7/8 (n = 169) HLA-
matched unrelated donors or with UCB (n = 252). All
patients were aged 16 to 54 years at diagnosis, and patients
given in vivo or ex vivo T-cell depletion of the graft were
excluded. Further, only patients transplanted in CR1 from 2
to 6 months after diagnosis for UCBT and from 4 to
10 months after diagnosis for unrelated BMT were included.
Main observations were that, in the baseline analyses, 5-year
OS was 60% for unrelated BMT recipients (results were
similar in the group of patients given 8/8 HLA-matched
BMT or 7/8 HLA-matched BMT) versus 52% for UCB
recipients. In sensitivity analyses, superiority of unrelated
BMT over UCBT was consistently observed when the time
from CR1 to unrelated BMT varied from 3 to 9 months, and
the same held true for 7/8 HLA-matched unrelated BMT
versus UCB. Given the lower incidence of chronic GVHD
associated with UCBT, the authors performed additional
analyses adjusted for quality of live (QOL) taking into
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consideration being alive with or without chronic GVHD at
5 years. In these analyses, a value of 98 was assigned to
patients alive without chronic GVHD at 5 years, a value of
0 was assigned to death patients, and a value of 70 (with a
wide plausible range from 0 to 98) assigned to patients alive
with active chronic GVHD at 5 years. Notably, the expected
OS rate for unrelated BMT remained higher than for UCBT
when the utility of being alive with active GVHD was var-
ied between 0 and 98. The authors concluded that, based on
their results, 8/8 or 7/8 UBMT is a better transplantation
approach than UCBT even after taking into consideration
the time required for donor coordination.
This study adds important information on the best allo-
geneic transplantation strategies for patients with AML in
CR1 who lack an HLA-identical sibling donor, and the
authors should be congratulated for having conducted thor-
ough statistical analyses taking into consideration the differ-
ent times requested to perform unrelated BMT or UCBT.
However, this study has also some limitations such as the
relative small number of patients included in the UCB group
(n = 252), the lack of data on reason for performing UCB
or unrelated BMT, the lack of data on genetic AML marker
(which has been demonstrated to have an important impact
on post-transplantation outcomes (5)), and the inclusion in
the UCBT group patients who were given <2.5 9 10E7
TNC/kg that might be considered as inadequate. Thus, more
studies are needed before it can be definitively concluded
that BMT with a 7/8 HLA-matched unrelated donor results
in better outcome than UCBT.
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